Rocklatan header logo
MENU CLOSE

Reducing treatment burden may start with once-daily dosing1,2,3

Rocklatan® is a once-daily ophthalmic solution that contains 0.02% netarsudil ophthalmic solution and 0.005% latanoprost ophthalmic solution.4 What does that mean for patients?

QD dosing icon

Once-daily dosing from a single bottle means Rocklatan® may help patients1,2,3:

  • Reduce treatment burden with a once-a-day dosing schedule
  • Improve adherence with the convenience of a single bottle
  • Reduce the risk of disease progression through improved adherence

Help improve overall treatment compliance for patients with open-angle glaucoma and ocular hypertension1,2,3


Administration and Storage4

Rocklatan® only requires one drop of medication per day and should be taken in the evening.

If one dose is missed, treatment should continue with the next dose in the evening.

If Rocklatan® is to be used concomitantly with other topical ophthalmic products, administer each product at least 5 minutes apart.

The dosage for Rocklatan® should not exceed once daily.

Storing Rocklatan®

Protect from light. Store Rocklatan® in the refrigerator (36°–46°F).

For any additional questions on storage or handling, view full Prescribing Information.


IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent.

Gradual change to eyelashes may include increased length, thickness, number, and misdirected growth of lashes. Usually reversible upon discontinuation of treatment.

Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). Should generally not be used in patients with active intraocular inflammation.

Macular edema, including cystoid macular edema, has been reported with latanoprost. Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema.

Use with caution in patients with a history of herpetic keratitis. Avoid use in cases of active herpes simplex keratitis.

Bacterial keratitis has been reported with multiple-dose containers of topical ophthalmic products inadvertently contaminated by patients.

Remove contact lenses prior to administration and reinsert 15 minutes after administration.

Adverse reactions

The most common ocular adverse reactions were conjunctival hyperemia (59%), with 5% of patients discontinuing therapy for this reason, instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

INDICATIONS AND USAGE

Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

Please click here for full prescribing information for Rocklatan® Solution

To report Suspected Adverse Reactions, contact Aerie Pharmaceuticals, Inc. at 1-855-740-1924 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent.

Gradual change to eyelashes may include increased length, thickness, number, and misdirected growth of lashes. Usually reversible upon discontinuation of treatment.

Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). Should generally not be used in patients with active intraocular inflammation.

Macular edema, including cystoid macular edema, has been reported with latanoprost. Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema.

Use with caution in patients with a history of herpetic keratitis. Avoid use in cases of active herpes simplex keratitis.

Bacterial keratitis has been reported with multiple-dose containers of topical ophthalmic products inadvertently contaminated by patients.

Remove contact lenses prior to administration and reinsert 15 minutes after administration.

Adverse reactions

The most common ocular adverse reactions were conjunctival hyperemia (59%), with 5% of patients discontinuing therapy for this reason, instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

INDICATIONS AND USAGE

Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

Please click here for full prescribing information for Rocklatan® Solution

To report Suspected Adverse Reactions, contact Aerie Pharmaceuticals, Inc. at 1-855-740-1924 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References:

  1. Higginbotham E. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1-9
  2. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005 May;112(5):863-8.
  3. Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011 Jan;59 Suppl(Suppl1):S93-6.
  4. Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Prescribing Information, Aerie Pharmaceuticals, Inc., Irvine, Calif. 2020.